Cargando…

Potential drawbacks of SARS-CoV-2 seroprevalence surveys

Detalles Bibliográficos
Autor principal:	Lippi, G.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	The Healthcare Infection Society. Published by Elsevier Ltd. 2021
Materias:	Letter to the Editor
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7834203/ https://www.ncbi.nlm.nih.gov/pubmed/33358929 http://dx.doi.org/10.1016/j.jhin.2020.12.011

Ejemplares similares

Possible drawbacks of relying only on molecular testing for diagnosing SARS-CoV-2 infections
por: Lippi, G., et al.
Publicado: (2022)

Will all SARS-CoV-2 seroprevalence surveys provide the right picture?
por: Valent, F., et al.
Publicado: (2020)

Potential drawbacks of frequent asymptomatic coronavirus disease 2019 (COVID-19) testing
por: Lippi, Giuseppe, et al.
Publicado: (2020)

SARS-CoV-2 seroprevalence in the Vatican City State
por: Ralli, Massimo, et al.
Publicado: (2021)

The SARS-CoV-2 seroprevalence is the key factor for deconfinement in France
por: Dimeglio, Chloé, et al.
Publicado: (2020)

Seroprevalence of SARS-CoV-2 antibodies in radio and television workers
por: Martins-Filho, Paulo Ricardo, et al.
Publicado: (2022)

Seroprevalence of SARS-CoV-2 antibodies in low-income university students
por: Araújo, Adriano Antunes de Souza, et al.
Publicado: (2021)

High SARS-CoV-2 seroprevalence in HIV patients originating from sub-Saharan Africa in the Ile-de-France area: Seroprevalence of SARS-CoV-2 in HIV patients
por: ABDI, Basma, et al.
Publicado: (2022)

Repeated Testing in SARS-CoV-2 Infection
por: Lippi, Giuseppe, et al.
Publicado: (2020)

Anti-SARS-CoV-2 IgG antibodies in patients with or without SARS-CoV-2 infection after BNT162b2 vaccine booster
por: Salvagno, G.L., et al.
Publicado: (2022)

SARS-CoV-2 antibody seroprevalence in a large neuroimmunological patient cohort
por: Eisenhut, Katharina, et al.
Publicado: (2021)

Seroprevalence of SARS-CoV-2 antibodies in 2115 blood donors from Romania
por: Olariu, Tudor Rares, et al.
Publicado: (2021)

Seroprevalence of anti-SARS-CoV2 Antibodies in Umbrian Persons Living with HIV
por: Papalini, Chiara, et al.
Publicado: (2020)

Screening and confirmation tests for SARS-CoV-2: benefits and drawbacks
por: Shafie, Muhammad Hakimin, et al.
Publicado: (2023)

Highly efficient respirators are needed for the Omicron variant of SARS-CoV-2
por: Mattiuzzi, C., et al.
Publicado: (2022)

Has SARS-CoV-2 evolved and adapted to circulate at high temperatures?
por: Lippi, G., et al.
Publicado: (2022)

Rapid increase in SARS-CoV-2 seroprevalence during the emergence of Omicron variant, Finland
por: Ahava, Maarit J., et al.
Publicado: (2022)

COVID-19 vaccines efficacy in preventing or limiting SARS-CoV-2 infections
por: Mattiuzzi, Camilla, et al.
Publicado: (2022)

COVID-19 vaccination is highly effective to prevent SARS-CoV-2 circulation
por: Mattiuzzi, Camilla, et al.
Publicado: (2022)

Is diffusion of SARS-CoV-2 variants of concern associated with different symptoms?
por: Mattiuzzi, Camilla, et al.
Publicado: (2022)

The presence of anti–SARS-CoV-2 antibodies does not necessarily reflect efficient neutralization
por: Lippi, Giuseppe, et al.
Publicado: (2022)

Lower nasopharyngeal viral load in young SARS-CoV-2-positive subjects
por: Salvagno, Gian Luca, et al.
Publicado: (2021)

Post-SARS-CoV-2 vaccination specific antibody decrease — Thresholds for determining seroprevalence and seroneutralization differ
por: Douxfils, Jonathan, et al.
Publicado: (2021)

Seroprevalence of SARS-Cov-2 in 646 professionals at the Rothschild Foundation Hospital (ProSeCoV study)
por: Mesnil, Malcie, et al.
Publicado: (2020)

Seroprevalence of SARS-CoV-2 among blood donors: A practical serosurveillance tool for COVID-19
por: Bansal, N., et al.
Publicado: (2022)

Reliability of SARS-CoV-2 serological testing for influencing public health policies: A reappraisal
por: Lippi, Giuseppe, et al.
Publicado: (2023)

Aminoglycosides and their potential as SARS-CoV-2 antivirals
por: Cimolai, Nevio
Publicado: (2021)

Cellular immunity against SARS-CoV-2 depends on the serological status
por: Pighi, Laura, et al.
Publicado: (2023)

Drawbacks for Studies on the Essential Oil of Dracocephalum kotschyi
por: Quoc, Le Pham Tan
Publicado: (2023)

Detection of SARS-CoV-2 by Use of the Cepheid Xpert Xpress SARS-CoV-2 and Roche cobas SARS-CoV-2 Assays
por: Moran, Angelica, et al.
Publicado: (2020)

Rapid SARS-CoV-2 Seroprevalence Survey in Central and Western Divisions of Fiji, 2021
por: Curtis, Stephanie J., et al.
Publicado: (2023)

Disproportionate impact of SARS-CoV-2 on ethnic minority and frontline healthcare workers: A cross-sectional seroprevalence survey at a North London hospital
por: Martyn, Emily M., et al.
Publicado: (2021)

SARS-CoV-2 seroprevalence, seroconversion and neutralizing antibodies in a systemic lupus erythematosus cohort and comparison to controls
por: Mathew, Hannah R, et al.
Publicado: (2021)

Seroprevalence of antibodies against SARS-CoV-2 in a large national hospital and affiliated facility in Tokyo, Japan
por: Tanaka, Akihito, et al.
Publicado: (2021)

Seroprevalence of SARS-CoV-2 significantly varies with age: Preliminary results from a mass population screening
por: Pagani, Gabriele, et al.
Publicado: (2020)

SARS-CoV-2 seroprevalence in the adult detainees of the Paris area in 2021: A multicenter cross-sectional study
por: Mellon, Guillaume, et al.
Publicado: (2022)

SARS-CoV-2 Omicron infection is associated with high nasopharyngeal viral load
por: Salvagno, Gian Luca, et al.
Publicado: (2022)

Seroprevalence of SARS-CoV-2 antibodies in a national hospital and affiliated facility after the second epidemic wave of Japan
por: Yamamoto, Shohei, et al.
Publicado: (2021)

Role of molecular diagnostics in the clinical management of SARS-CoV-2 infection: advantages and drawbacks
por: Martín-Higuera, Carmen, et al.
Publicado: (2021)

Seroprevalence of SARS-CoV-2–Specific Antibodies, Faroe Islands
por: Petersen, Maria Skaalum, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_74sgb3nse2993ejmohueuf6j27